Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-202-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-16"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20110216.11.3-202-000"2
lpv:hasSubsequent	lp_eu:2011-02-16-Speech-3-203-0002
lpv:speaker	lp:Maria Da Graça Carvalho2
lpv:spokenAs	member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-04-30)3 unknown; Partido Social Democrata (2009-07-14--2014-04-30)3 substitute; Delegation for relations with the Palestinian Legislative Council (2009-09-16--2014-04-30)3 substitute; BUDG (2009-07-16--2012-01-18)3 substitute; Special committee on the policy challenges and budgetary resources for a sustainable European Union after 2013 (2010-06-17--2011-06-30)3 substitute; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-04-30)3 member; EPP (2009-07-14--2014-04-30)3 member; ITRE (2009-07-16--2012-01-18)3
lpv:translated text	"− We must act as a matter of urgency in response to the alarming increase in medicinal products which are falsified in relation to their identity, history or source. These products normally contain low-quality or falsified substances, representing a serious threat to public health, and also leading to a loss of patient trust in the legal supply chain. The verification requirements pharmaceutical manufacturers are subject to should be stepped up in order to avoid these risks. Safety features for medicines should also be harmonised within the EU, and should enable each individual pack to be identified and its authenticity verified. They should also identify any falsified products, while ensuring the functioning of the internal market for medicines. The risk-assessment process should take account of criteria such as the cost of medicines and the history of falsified medicines in the EU and in third countries, as well as the effects these falsified products have on public health, in terms of the specific nature of the products in question and of the severity of the conditions they are intended to treat. The safety features should enable the verification of every pack of medicine that is supplied, regardless of the method of supply used, including those available via distance-selling channels."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph